Novartis Ag Adr Stock Z Score

NVS Stock  USD 95.88  0.61  0.64%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Novartis Piotroski F Score and Novartis Valuation analysis.
  
At this time, Novartis' Net Invested Capital is comparatively stable compared to the past year. Net Working Capital is likely to gain to about 5.7 B in 2024, whereas Capital Lease Obligations is likely to drop slightly above 1.5 B in 2024. At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024.

Novartis Z Score Analysis

Novartis' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

Current Novartis Z Score

    
  6.3  
Most of Novartis' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Novartis Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Z Score. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
0.660.920.520.710.920.920.7-0.01-0.050.00.880.410.55-0.070.930.750.610.760.98-0.010.830.10.370.26-0.360.190.290.260.040.22
0.660.360.040.70.390.740.260.390.16-0.660.860.750.61-0.440.720.360.240.810.640.510.35-0.490.27-0.35-0.420.60.3-0.290.11-0.1
0.920.360.650.430.990.830.71-0.08-0.060.310.620.260.280.120.770.620.520.470.92-0.260.880.420.250.38-0.27-0.140.170.450.180.29
0.520.040.650.120.690.350.23-0.26-0.210.330.260.04-0.070.10.330.550.410.280.47-0.290.440.460.210.5-0.72-0.160.030.310.10.2
0.710.70.430.120.490.610.450.14-0.14-0.40.880.230.62-0.250.850.730.460.910.680.320.35-0.430.360.15-0.290.580.24-0.05-0.180.09
0.920.390.990.690.490.820.7-0.05-0.120.240.650.270.270.060.80.680.560.540.92-0.180.840.380.310.38-0.36-0.070.20.40.20.27
0.920.740.830.350.610.820.65-0.010.14-0.10.840.430.49-0.120.870.580.360.660.94-0.010.87-0.010.180.09-0.280.140.150.070.020.15
0.70.260.710.230.450.70.65-0.28-0.50.290.530.040.29-0.030.690.460.370.440.77-0.280.80.230.270.210.060.030.110.18-0.030.1
-0.010.39-0.08-0.260.14-0.05-0.01-0.280.22-0.50.080.67-0.06-0.120.08-0.29-0.160.17-0.030.51-0.35-0.160.05-0.53-0.010.20.240.010.76-0.01
-0.050.16-0.06-0.21-0.14-0.120.14-0.50.22-0.21-0.020.190.090.09-0.11-0.2-0.2-0.22-0.080.12-0.03-0.16-0.25-0.170.13-0.18-0.03-0.01-0.010.05
0.0-0.660.310.33-0.40.24-0.10.29-0.5-0.21-0.36-0.54-0.290.74-0.16-0.020.07-0.480.05-0.830.30.85-0.150.650.39-0.77-0.330.75-0.130.54
0.880.860.620.260.880.650.840.530.08-0.02-0.360.490.75-0.270.920.740.590.930.850.280.59-0.290.430.08-0.390.530.37-0.02-0.120.1
0.410.750.260.040.230.270.430.040.670.19-0.540.490.36-0.380.36-0.020.230.480.360.530.11-0.150.35-0.57-0.340.420.51-0.120.58-0.16
0.550.610.28-0.070.620.270.490.29-0.060.09-0.290.750.36-0.250.620.530.630.620.490.360.29-0.350.59-0.04-0.060.520.510.0-0.360.01
-0.07-0.440.120.1-0.250.06-0.12-0.03-0.120.090.74-0.27-0.38-0.25-0.19-0.11-0.03-0.39-0.05-0.750.030.72-0.360.670.48-0.77-0.370.84-0.110.9
0.930.720.770.330.850.80.870.690.08-0.11-0.160.920.360.62-0.190.760.520.830.930.150.69-0.120.420.13-0.310.330.30.110.020.13
0.750.360.620.550.730.680.580.46-0.29-0.2-0.020.74-0.020.53-0.110.760.760.740.680.090.52-0.040.50.52-0.470.320.320.15-0.290.18
0.610.240.520.410.460.560.360.37-0.16-0.20.070.590.230.63-0.030.520.760.580.50.120.350.20.790.41-0.260.330.70.35-0.10.22
0.760.810.470.280.910.540.660.440.17-0.22-0.480.930.480.62-0.390.830.740.580.710.420.38-0.360.510.04-0.530.710.41-0.13-0.040.0
0.980.640.920.470.680.920.940.77-0.03-0.080.050.850.360.49-0.050.930.680.50.71-0.060.870.120.30.22-0.290.110.180.240.040.22
-0.010.51-0.26-0.290.32-0.18-0.01-0.280.510.12-0.830.280.530.36-0.750.150.090.120.42-0.06-0.32-0.710.4-0.63-0.310.760.39-0.580.2-0.56
0.830.350.880.440.350.840.870.8-0.35-0.030.30.590.110.290.030.690.520.350.380.87-0.320.270.070.31-0.12-0.11-0.010.22-0.090.14
0.1-0.490.420.46-0.430.38-0.010.23-0.16-0.160.85-0.29-0.15-0.350.72-0.12-0.040.2-0.360.12-0.710.270.00.520.2-0.74-0.050.80.280.6
0.370.270.250.210.360.310.180.270.05-0.25-0.150.430.350.59-0.360.420.50.790.510.30.40.070.0-0.06-0.270.50.810.040.1-0.12
0.26-0.350.380.50.150.380.090.21-0.53-0.170.650.08-0.57-0.040.670.130.520.410.040.22-0.630.310.52-0.060.02-0.38-0.210.66-0.440.69
-0.36-0.42-0.27-0.72-0.29-0.36-0.280.06-0.010.130.39-0.39-0.34-0.060.48-0.31-0.47-0.26-0.53-0.29-0.31-0.120.2-0.270.02-0.4-0.190.33-0.120.29
0.190.6-0.14-0.160.58-0.070.140.030.2-0.18-0.770.530.420.52-0.770.330.320.330.710.110.76-0.11-0.740.5-0.38-0.40.5-0.57-0.08-0.53
0.290.30.170.030.240.20.150.110.24-0.03-0.330.370.510.51-0.370.30.320.70.410.180.39-0.01-0.050.81-0.21-0.190.5-0.030.3-0.19
0.26-0.290.450.31-0.050.40.070.180.01-0.010.75-0.02-0.120.00.840.110.150.35-0.130.24-0.580.220.80.040.660.33-0.57-0.030.10.82
0.040.110.180.1-0.180.20.02-0.030.76-0.01-0.13-0.120.58-0.36-0.110.02-0.29-0.1-0.040.040.2-0.090.280.1-0.44-0.12-0.080.30.1-0.11
0.22-0.10.290.20.090.270.150.1-0.010.050.540.1-0.160.010.90.130.180.220.00.22-0.560.140.6-0.120.690.29-0.53-0.190.82-0.11
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

Based on the company's disclosures, Novartis AG ADR has a Z Score of 6.3. This is 6.67% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The z score for all United States stocks is 27.75% higher than that of the company.

Novartis Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.
Novartis is currently under evaluation in z score category among related companies.

Novartis Institutional Holders

Institutional Holdings refers to the ownership stake in Novartis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novartis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novartis' value.
Shares
Principal Financial Group Inc2023-12-31
2.5 M
Northern Trust Corp2023-12-31
2.1 M
Envestnet Asset Management Inc2023-12-31
M
Wells Fargo & Co2023-12-31
M
Blackrock Inc2023-12-31
1.8 M
State Street Corporation2023-12-31
1.8 M
Ubs Group Ag2023-12-31
1.7 M
Cullen Capital Management, Llc2023-12-31
1.6 M
Grantham, Mayo, Van Otterloo & Co., Llc2023-12-31
1.5 M
Dodge & Cox2023-12-31
13.2 M
Primecap Management Company2023-12-31
12.9 M

Novartis Fundamentals

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people.

Novartis Investors Sentiment

The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Novartis Piotroski F Score and Novartis Valuation analysis.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.